Cardiac myosin inhibitor
Mavacamten
Brand names: Camzyos
Adult dose
Dose: 5mg PO OD; titrate by 5mg increments at 4-week intervals to max 15mg/day per echo response
Route: PO
Frequency: OD
Clinical pearls
- Symptomatic obstructive hypertrophic cardiomyopathy
- REMS/Risk-management programme; echo every 12 weeks; CYP2C19 genotyping advisable
Contraindications
- LVEF <55%
- Concurrent moderate/strong CYP2C19 inhibitor / strong CYP3A4 inducer
- Pregnancy
Side effects
- Heart failure (reduced LVEF)
- Atrial fibrillation
- Dizziness
- Syncope
Interactions
- CYP2C19 / CYP3A4 modulators
- Negative inotropes (β-blockers/CCBs/disopyramide)
Monitoring
- Echo (LVEF, gradient) every 12 weeks
- Symptoms
Reference: BNF; NICE TA913; SmPC; https://bnf.nice.org.uk/drugs/mavacamten/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines